Therapeutically, inhibition of the WNT/β-catenin pathway in Ewing sarcoma with the PORCN inhibitor, WNT974, decreases metastatic Ewing sarcoma in a mouse model but does not affect overall survival [127]. The gene discussed is PORCN; the disease is Ewing sarcoma.